Abstract
We investigated the association of plasma AGE (advanced glycation end product) concentration with central and peripheral blood pressures and central-to-brachial blood pressure amplification in a Chinese population. The study subjects were from a newly established residential area in the suburb of Shanghai. Using the SphygmoCor system, we recorded radial arterial waveforms and derived aortic waveforms by a generalized transfer function and central systolic and pulse pressure by calibration for brachial blood pressure measured with an oscillometric device. The central-to-brachial pressure amplification was expressed as the central-to-brachial systolic blood pressure difference and pulse pressure difference and ratio. Plasma AGE concentration was measured by the enzyme-linked immunosorbent assay method and logarithmically transformed for statistical analysis. The 1051 participants (age, 55.1±13.1 years) included 663 women. After adjustment for sex, age and other confounding factors, plasma AGE concentration was associated with central but not peripheral blood pressures and with some of the pressure amplification indexes. Indeed, each 10-fold increase in plasma AGE concentration was associated with 2.94 mm Hg (P=0.04) higher central systolic blood pressure and 2.39% lower central-to-brachial pulse pressure ratio (P=0.03). In further subgroup analyses, the association was more prominent in the presence of hypercholesterolemia (+8.11 mm Hg, P=0.008) for central systolic blood pressure and in the presence of overweight and obesity (−4.89%, P=0.009), diabetes and prediabetes (−6.26%, P=0.10) or current smoking (−6.68%, P=0.045) for central-to-brachial pulse pressure ratio. In conclusion, plasma AGE concentration is independently associated with central systolic blood pressure and pulse pressure amplification, especially in the presence of several modifiable cardiovascular risk factors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Basta G, Schmidt AM, De Caterina R . Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63: 582–592.
Goh SY, Cooper ME . Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143–1152.
Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 1997; 94: 13915–13920.
Luevano-Contreras C, Chapman-Novakofski K . Dietary advanced glycation end products and aging. Nutrients 2010; 2: 1247–1265.
Bohlender JM, Franke S, Stein G, Wolf G . Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005; 289: F645–F659.
McRobert EA, Young AN, Bach LA . Advanced glycation end-products induce calpain-mediated degradation of ezrin. FEBS J 2012; 279: 3240–3250.
Hegab Z, Gibbons S, Neyses L, Mamas MA . Role of advanced glycation end products in cardiovascular disease. World J Cardiol 2012; 4: 90–102.
Zieman SJ, Melenovsky V, Kass DA . Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25: 932–943.
Francis-Sedlak ME, Uriel S, Larson JC, Greisler HP, Venerus DC, Brey EM . Characterization of type I collagen gels modified by glycation. Biomaterials 2009; 30: 1851–1856.
Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, DeGroof RC et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104: 1464–1470.
Huang QF, Sheng CS, Liu M, Li FH, Li Y, Wang JG . Arterial stiffness and wave reflections in relation to plasma advanced glycation end products in a Chinese population. Am J Hypertens 2013; 26: 754–761.
Nichols WW, O'Rourke MF . McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles, 5th edn. Oxford University Press: Oxford, UK, 2005, p 624.
Wang KL, Cheng HM, Chuang SY, Spurgeon HA, Ting CT, Lakatta EG et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens 2009; 27: 461–467.
Huang CM, Wang KL, Cheng HM, Chuang SY, Sung SH, Yu WC et al. Central versus ambulatory blood pressure in the prediction of all-cause and cardiovascular mortalities. J Hypertens 2011; 29: 454–459.
Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007; 50: 197–203.
Dart AM, Gatzka CD, Kingwell BA, Willson K, Cameron JD, Liang YL et al. Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives. Hypertension 2006; 47: 785–790.
Sheng CS, Hu BC, Fan WX, Zou J, Li Y, Wang JG . Microalbuminuria in relation to the metabolic syndrome and its components in a Chinese population. Diabetol Metab Syndr 2011; 3: 6.
Engelen L, Stehouwer CD, Schalkwijk CG . Current therapeutic interventions in the glycation pathway: evidence from clinical studies. Diabetes Obes Metab 2013; 15: 677–689.
Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588–2605.
Safar ME, Protogerou AD, Blacher J . Statins, central blood pressure, and blood pressure amplification. Circulation 2009; 119: 9–12.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–1357.
Rabbani N, Thornalley PJ . The critical role of methylglyoxal and glyoxalase 1 in diabetic nephropathy. Diabetes 2014; 63: 50–52.
Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashina A . Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. Hypertens Res 2007; 30: 219–228.
Ding FH, Li Y, Zhang RY, Zhang Q, Wang JG . Comparison of the SphygmoCor and Omron devices in the estimation of pressure amplification against the invasive catheter measurement. J Hypertens 2013; 31: 86–93.
McEniery CM, Yasmin, McDonnell B, Munnery M, Wallace SM, Rowe CV et al. Central pressure: variability and impact of cardiovascular risk factors: the Anglo-Cardiff Collaborative Trial II. Hypertension 2008; 51: 1476–1482.
Sharman J, Stowasser M, Fassett R, Marwick T, Franklin S . Central blood pressure measurement may improve risk stratification. J Hum Hypertens 2008; 22: 838–844.
Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004; 47: 1324–1330.
Acknowledgements
We gratefully acknowledge the voluntary participation of all study subjects and the technical assistance of the physicians and nurses of Zhaoxiang Community Health Centre (Qingpu District, Shanghai). We also appreciate the expert assistance of Jie Wang and Wei-Zhong Zhang (The Shanghai Institute of Hypertension, China). The present study was financially supported by grants from the National Natural Science Foundation of China (Grant Nos. 81170245, 81270373, 81470533 and 81400312), the Ministry of Science and Technology (Grant No. 2013CB530700 and a grant for China-European Union collaborations (1012)) and the Ministry of Education (NCET-09-0544), Beijing China, the Shanghai Commissions of Science and Technology (Grant Nos. 11QH1402000 and 14ZR1436200) and Education (Grant No. JDY09088), the Shanghai Bureau of Health (Grant Nos. XBR2011004, 20101051 and 20144Y0213) and Shanghai Jiaotong University School of Medicine (Grant No. 14XJ10071).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Huang, QF., Sheng, CS., Kang, YY. et al. Central and peripheral blood pressures in relation to plasma advanced glycation end products in a Chinese population. J Hum Hypertens 30, 430–435 (2016). https://doi.org/10.1038/jhh.2015.60
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhh.2015.60
This article is cited by
-
Clinic and ambulatory blood pressure in relation to the interaction between plasma advanced glycation end products and sodium dietary intake and renal handling
Hypertension Research (2022)
-
No significant association of serum klotho concentration with blood pressure and pulse wave velocity in a Chinese population
Scientific Reports (2021)
-
Determinants of pulse pressure amplification in hypertensive and diabetic patients
Hypertension Research (2019)